On November 22, 2023, Femasys Inc. closed the transaction. The company received $1,850,000 in its second and final tranche. The company received funding pursuant to Regulation D in the transaction from 4 investors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.21 USD | -4.72% | -6.20% | +24.10% |
05-09 | Femasys Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-09 | Earnings Flash (FEMY) FEMASYS Reports Q1 Revenue $271,140 | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2.155 USD | -0.99% | +2.13% | 18.22M | ||
1.21 USD | -4.72% | -6.20% | 26.74M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.10% | 26.74M | |
-4.84% | 182B | |
+0.56% | 110B | |
-3.35% | 68.11B | |
+2.39% | 50.53B | |
+9.36% | 44.8B | |
+2.70% | 40.7B | |
+24.51% | 32.3B | |
+3.43% | 26.53B | |
+13.67% | 25.02B |
- Stock Market
- Equities
- FEMY Stock
- News Femasys Inc.
- Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors